Pulmonx Past Earnings Performance
Past criteria checks 0/6
Pulmonx's earnings have been declining at an average annual rate of -19%, while the Medical Equipment industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 20.3% per year.
Key information
-19.0%
Earnings growth rate
57.1%
EPS growth rate
| Medical Equipment Industry Growth | 8.9% |
| Revenue growth rate | 20.3% |
| Return on equity | -60.8% |
| Net Margin | -72.0% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Not Many Are Piling Into Pulmonx Corporation (NASDAQ:LUNG) Stock Yet As It Plummets 27%
Oct 22
Is Pulmonx (NASDAQ:LUNG) Using Debt In A Risky Way?
Oct 02Pulmonx Corporation (NASDAQ:LUNG) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Aug 15Pulmonx: Low Bar For Q2 Earnings
Jul 21Slammed 26% Pulmonx Corporation (NASDAQ:LUNG) Screens Well Here But There Might Be A Catch
Jun 07Pulmonx Corporation's (NASDAQ:LUNG) Share Price Matching Investor Opinion
Apr 04Pulmonx: Revisiting Thesis Following Management Change
Mar 26Pulmonx (NASDAQ:LUNG) Has Debt But No Earnings; Should You Worry?
Feb 23Market Participants Recognise Pulmonx Corporation's (NASDAQ:LUNG) Revenues
Aug 01Analysts Just Shaved Their Pulmonx Corporation (NASDAQ:LUNG) Forecasts Dramatically
Nov 08Pulmonx GAAP EPS of -$0.40 in-line, revenue of $14M beats by $0.23M
Aug 02Pulmonx: Interesting Technology But Struggling With Adoption
Jul 02These Analysts Just Made A Meaningful Downgrade To Their Pulmonx Corporation (NASDAQ:LUNG) EPS Forecasts
Feb 28Revenue & Expenses Breakdown
How Pulmonx makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 79 | -57 | 100 | 16 |
| 30 Jun 24 | 77 | -58 | 98 | 18 |
| 31 Mar 24 | 73 | -59 | 96 | 18 |
| 31 Dec 23 | 69 | -61 | 95 | 18 |
| 30 Sep 23 | 65 | -61 | 92 | 18 |
| 30 Jun 23 | 61 | -61 | 88 | 18 |
| 31 Mar 23 | 57 | -59 | 86 | 16 |
| 31 Dec 22 | 54 | -59 | 83 | 15 |
| 30 Sep 22 | 52 | -58 | 80 | 15 |
| 30 Jun 22 | 52 | -54 | 77 | 14 |
| 31 Mar 22 | 50 | -52 | 74 | 14 |
| 31 Dec 21 | 48 | -49 | 70 | 13 |
| 30 Sep 21 | 45 | -45 | 65 | 12 |
| 30 Jun 21 | 42 | -39 | 59 | 11 |
| 31 Mar 21 | 33 | -38 | 52 | 9 |
| 31 Dec 20 | 33 | -32 | 46 | 7 |
| 30 Sep 20 | 33 | -28 | 42 | 7 |
| 30 Jun 20 | 32 | -28 | 40 | 6 |
| 31 Mar 20 | 35 | -22 | 37 | 6 |
| 31 Dec 19 | 33 | -21 | 34 | 6 |
| 31 Dec 18 | 20 | -18 | 20 | 7 |
Quality Earnings: LUNG is currently unprofitable.
Growing Profit Margin: LUNG is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LUNG is unprofitable, and losses have increased over the past 5 years at a rate of 19% per year.
Accelerating Growth: Unable to compare LUNG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LUNG is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (15%).
Return on Equity
High ROE: LUNG has a negative Return on Equity (-60.8%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 20:37 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Pulmonx Corporation is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Travis Steed | BofA Global Research |
| William Plovanic | Canaccord Genuity |
| John Young | Canaccord Genuity |